| Literature DB >> 35966450 |
Bahriye Eryildiz1,2, Bahar Yavuzturk Gul2,3, Ismail Koyuncu1,2.
Abstract
In the last years, antiviral drugs especially used for the treatment of COVID-19 have been considered emerging contaminants because of their continuous occurrence and persistence in water/wastewater even at low concentrations. Furthermore, as compared to antiviral drugs, their metabolites and transformation products of these pharmaceuticals are more persistent in the environment. They have been found in environmental matrices all over the world, demonstrating that conventional treatment technologies are unsuccessful for removing them from water/wastewater. Several approaches for degrading/removing antiviral drugs have been studied to avoid this contamination. In this study, the present level of knowledge on the input sources, occurrence, determination methods and, especially, the degradation and removal methods of antiviral drugs are discussed in water/wastewater. Different removal methods, such as conventional treatment methods (i.e. activated sludge), advanced oxidation processes (AOPs), adsorption, membrane processes, and combined processes, were evaluated. In addition, the antiviral drugs and these metabolites, as well as the transformation products created as a result of treatment, were examined. Future perspectives for removing antiviral drugs, their metabolites, and transformation products were also considered.Entities:
Keywords: Antiviral drugs; COVID-19; Determination methods; Removal process; SARS-CoV-2; Virus
Year: 2022 PMID: 35966450 PMCID: PMC9359512 DOI: 10.1016/j.jwpe.2022.103036
Source DB: PubMed Journal: J Water Process Eng ISSN: 2214-7144
Physicochemical properties of some antiviral drugs.
| Virus | Antiviral drug | Trade name | Formula | Molecular weight (MW) (g/mol) | Log Kow | pKa | Bioavailability |
|---|---|---|---|---|---|---|---|
| HIV | Abacavir | Ziagen | C14H18N6O | 286.33 | 1.2 | 15.41, 5.8 | 1 |
| Zidovudine | Retrovir | C10H13N5O4 | 267.24 | 0.05 | 9.96, −3 | 1 | |
| Lamivudine | Epivir | C8H11N3O3S | 229.26 | −9.54 | 14.29, −0.16 | 1 | |
| Stavudine | Zerit | C10H12N2O4 | 224.21 | −0.72 | 9.95, −3 | 1 | |
| Nevirapine | Viramune | C15H12N2O4 | 266.29 | 3.89 | 14.98, 3.28 | 1 | |
| HSVs | Acyclovir | Zovirax | C8H11N5O3 | 225.20 | −1.56 | 11.98, 3.02 | 1 |
| Famciclovir | Famvir | C14H19N5O4 | 321.33 | 0.64 | 16.68, 3.65 | 1 | |
| Penciclovir | Denavir | C10H15N5O3 | 253.25 | −1.14 | 12, 2.88 | 1 | |
| Influenza | Amantadine | Gocovri | C10H17N | 151.24 | 2.44 | -, 10.71 | 1 |
| Oseltamivir | Tamiflu | C16H28N2O4 | 312.4 | 0.95 | 14.03, 9.31 | 1 | |
| Zanamivir | Relenza | C12H20N4O7 | 332.3 | −4.66 | 3.06, 11.93 | 0 | |
| SARS-CoV-2 | Favipiravir | Favipiravir | C5H4FN3O2 | 157.1 | – | 9.39, −3.7 | 1 |
| Remdesivir | Veklury | C27H35N6O8P | 602.58 | – | 10.23, 0.65 | 0 |
at 37 °C.
Fig. 1The fate of antiviral drugs in the environment.
Fig. 2Analysis method for detection of antiviral drugs (1) samples (2) extraction (3) instrumental analysis (4) data acquisition.
Determination methods for antiviral drugs in water/wastewater.
| Antiviral drug | Metabolite | Matrix | Extraction | Detection method | Wavelength (nm) | Measuring range | References |
|---|---|---|---|---|---|---|---|
| Acyclovir | – | Aqueous solution | – | UV–Vis spectrophotometer | 760 | – | |
| Sofosbuvir | – | Aqueous solution | – | UV–Vis spectrophotometer | 260 | – | |
| Oseltamivir | Oseltamivir carboxylate | Aqueous solution | – | HPLC system tandem with a triple quadrupole mass spectrometer with electro-spray ionization (ESI) | – | – | |
| Staduvine | – | Wastewater treatment plant influent and effluent | – | HPLC equipped with a fluorescent detector (FLD) | – | – | |
| Acyclovir | – | Aqueous solution | – | High-performance liquid chromatograph equipped with a VP-ODS column and SPD-M20A photodiode array detector | 254 | – | |
| – | Oseltamivir carboxylate | Synthetic river water | SPE | LC-MS/MS | – | 2–20 ng/L (LOQ) | |
| Oseltamivir | – | Aqueous solution | – | HPLC with UV detection | 230 | – | |
| Acyclovir | – | Aqueous solution | – | HPLC | – | – | |
| Acyclovir | – | Reverse osmosis brine | – | HPLC with UV detection | 254 | – | |
| Acyclovir | Pure water | – | Spectrophotometer | 297, 302, 313, 334, 365 and 366 | – | ||
| Oseltamivir | Oseltamivir carboxylate | River water | – | UPCL-MS/MS with electro-spray ionization (ESI) | – | – | |
| Zanamivir | – | Artificial fresh water | – | – | – | ||
| Zidovudine | – | Municipal wastewater | SPE | LC-MS/MS | – | – | |
| Favipiravir | Oseltamivir carboxylate | River water | SPE | LC-MS/MS | – | 0.1–0.2 ng/L (LOD) | |
| Zidovudine | – | Aqueous solution | – | HPLC | – | – | |
| Oseltamivir | – | Synthetic wastewater | – | HPLC with UV detection | 215 | 0.2 μM (detection limit) | |
| Acyclovir | – | Aqueous solution | – | HPLC | 254 | – | |
| Lamivudine | – | Aqueous solution | – | HPLC | 275 | – | |
| Oseltamivir phosphate (Tamiflu) | – | Aqueous solution | – | HPLC | 215 | 0.2 μM (detection limit) | |
| Abacavir | – | Aqueous solution | – | HPLC | 271 | – | |
| Lamivudine | – | Aqueous solution | – | HPLC | – | – | |
| Oseltamivir phosphate | Oseltamivir carboxylate | Aqueous solution | – | HPLC with UV detection | 220 | – | |
| Acyclovir | – | Hospital wastewater | SPE | UPLC-MS/MS | – | – | |
| Acyclovir | – | Pharmaceutical wastewaters | – | HPLC/MS | – | – | |
| Acyclovir | – | Wastewater treatment plant influent and effluent | – | LC-MS | – | – | |
| Acyclovir | – | Anaerobic sludge | – | LC-ESI-MS/MS | – | – | |
| Acyclovir | – | Synthetic wastewater | SPE | UFLC- 4000 QTRAP hybrid | – | – | |
| Acyclovir | – | Urban and hospital wastewater | SPE | LC-MS/MS | – | 0.03–50.6 ng/L (LOD) | |
| Abacavir | – | Wastewater treatment plant influent and effluent | – | LC-tandem-MS and HPLC | – | – | |
| Oseltamivir | – | Wastewater treatment plant influent and effluent | SPE | LC/MS/MS with ESI-positive ion mode | – | 0.30 ng/L (LOD) | |
| – | Oseltamivir carboxylate | Synthetic wastewater | – | LC/MS | – | – | |
| Acyclovir Lamivudine | – | Municipal wastewater | SPE | LC/MS | – | – | |
| Acyclovir | – | Pharmaceutical wastewater | – | HPLC/MS | – | 0.5 μg/L | |
| Acyclovir | – | Wastewater treatment plant effluent | – | LC/MS | – | – | |
| Oseltamivir | Oseltamivir carboxylate | Hospital wastewater | SPE | HPLC-MS/MS | – | – | |
| Acyclovir | – | Wastewater treatment plant secondary effluent | – | HPLC-MS | – | 25 ng/L (LOQ) | |
| Acyclovir | – | Wastewater treatment plant effluent | – | HPLC-MS/MS | – | 0.025 μg/L (LOQ) | |
| Acyclovir | – | Wastewater treatment plant effluent | – | LC-MS/MS | – | 0.0001 mg/L | |
| Abacavir | – | Wastewater treatment plant influent and effluent | SPE | LC-MS/MS | – | 2–20 ng/L | |
| – | Wastewater treatment plant influent and effluent | SPE | LC-MS/MS | – | 0.1–1.9 ng/L |
Fig. 3Possible transport ways and the fate of the virus in the environment.
Virus detection on water and wastewater.
| Disease | Virus | Source | Concentration method | RNA detection method | Virus concentration | References |
|---|---|---|---|---|---|---|
| Herpes | Herpes Simplex virüs (HSV) | Wastewater treatment center aerosols | The Coriolis®μ (a liquid cyclone) | qPCR, Illumina MiSeq | %3,4-12,1 | |
| Influenza | Avian influenza virus H5N2 | River delta wetland | ND. | qRT-PCR | 0.91 EID50/ml, | |
| Influenza-A | Fecal and water samples were collected at migratory stopover sites | Filter-concentration through cation charged filters (CCF) | qRT-PCR) | 53 % stopover sites, 7 % and 4.8 % of the fecal and water samples | ||
| COVID-19 | SARS-CoV-2 | WWTP | Electronegative membrane, ultrafiltration | qRT-PCR | 22 % | |
| Sewage samples | Ultrafiltration | qRT-PCR | 2,6–2200 gene copies per mL | |||
| Sewage samples | PEG-NaCl precipitation | qRT-PCR | 57–303 copies per ml | |||
| Primary sewage sludge | ND | qRT-PCR | 1.7 × 103–4.6 × 105 ml−1 copies per ml | |||
| WWTP | Ultracentrifugation-based method | qRT-PCR | 3.1 to 7.1 log10 genome copies /100 mL | |||
| WWTP | Two-phase separation method, high-speed centrifugation | qRT-PCR | ND | |||
| WWTP | Ultrafiltration and an adsorption–elution method using electronegative membranes | qRT-PCR | 7.5 × 103 copies/L from the N1 assay and 3.1 × 103 and 4.3 × 103 copies/LFrom the N2 assay | |||
| Raw wastewater | PEG precipitation, centrifugation | qRT-PCR | 103 to 105 genome copies per liter (GC/L) | |||
| Municipal and hospital wastewater | Filtration 80.45-μm pore size) and centrifugal filter with a cutoff of 10 kDa | qRT-PCR | 19.73 % positive | |||
| River waters | Electronegative membrane-vortex (EMV) method | qRT-PCR | ND | |||
| River waters | Skimmed Milk Flocculation method, centrifugation | qRT-PCR | N1: 2,91E+05 to 3,19E+06 GC/L | |||
| River waters | ND | Real-time RT-PCR and infectivity test on culture cells | Positive nucleocapsid (N) gene and the Orf1ab gene |
Advantages and disadvantages of removal methods for antiviral drugs.
| Methods | Advantages | Disadvantages | References |
|---|---|---|---|
| Adsorption | Easy design | Expensive adsorbents | |
| Photolysis (UV-based) | Rapid reaction rate | Transformation products can be more | |
| Ozonation | Generation of more biodegradable products | Generation of more harmful by-products | |
| Photocatalysis | Cost-effective | Rare applicability in the real system | |
| The electrochemical advanced oxidation process | Highly effective | Expensive electrodes | |
| Activated sludge process | Cheaper investment cost | Generation of transformation products that can be harmful | |
| Membrane bioreactor | High-quality permeate | Biofouling |
Non-biological technologies for the treatment of antiviral drugs.
| Antiviral Drugs | Matrix | Concentration | Treatment Technology | Process Conditions | Removal or Q(mg/g) | References |
|---|---|---|---|---|---|---|
| Acyclovir | Distilled water | 400 mg/L | Adsorption | Temperature: 39 °C, pH:8: powdered adsorbent activated carbon, adsorbent dose: 2 g/L | 90.3 % | |
| Sofosbuvir | Distilled water | 0.1 mM | Adsorption | pH: 6.8, adsorbent: e- perlite | 58.5 % | |
| Didanosine, Nevirapine, Ritonavir, Efavirenz, Stavudine | Wastewater treatment plant influent and effluent | 0.5–1.25 mg/L | Adsorption | Contact time:15 min to 120 min, temperature: 15 to 60 °C,pH: 3 to 12 | 64.9 mg/g-200.5 mg/g | |
| Acyclovir | Distilled water | 100 mg/L | Adsorption | Temperature: 45 °C, pH:11, adsorbent: powdered activated charcoal, adsorbent dose: 4 g/L, equilibrium contact time: 75 min. | 98 % | |
| Zidovudine (ZDV) | Wastewater treatment plant effluent | 20 μM | Photolysis (UV) | pH:7.7–8.1, electrical energy dose: 6.67 kWh/103 L H2O2 dose:20.4 mg/L, Cl2 dose:42.6 mg/L | ZDV: >90 % | |
| UV/H2O2 | ZDV: >90 % | |||||
| UV/Cl2 | ZDV:~90 % | |||||
| Acyclovir | Open-water treatment | 302 ± 58 ng/L | Photolysis | Depth: 25–30 cm, pH: 7.7–9.0 | 70 % | |
| Acyclovir (ACV) | RO brine A and B from municipal wastewater reuse facilities | 5 μM | UV/H2O2 | Incident UV fluence: 1000 mJ/cm2 | ACV: ~35 % (RO Brine A) | |
| UV/S2O82− | ACV: ~30 % (RO Brine A) | |||||
| Oseltamivir acid (the active metabolite of Tamiflu®) | Secondary effluent in pilot-scale WWTP | 1 μM | Ozonation (O3) | >0.3 g O3 g−1 DOC | >50 % | |
| Tamiflu (oseltamivir phosphate) | Ultrapure water | 21 μM | Photocatalysis | P25 (one of the powdered TiO2) concentration: 20 and 100 mg/ L | >95 % | |
| Abacavir | Deionized water | – | Electrochemical Degradation | Anode:Ti/SnO2-Sb | >97 % | |
| Lamivudine | Deionized water | 2.5 mg/L | Electrochemical Degradation | Current density: 10 mA/cm2 | 98.3 % | |
| Initial pH:6.7 |
Biological technologies for the treatment of antiviral drugs.
| Antiviral drugs | Matrix | Concentration | Treatment technology | Process conditions | Removal | References |
|---|---|---|---|---|---|---|
| Oseltamivir | Municipal sewage treatment plant influent | 5–100 ng/L | Activated sludge process | Effluent quantity:~49 m3, Temperature: 27 °C | <50 % | |
| Acyclovir | Three pharmaceutical wastewater | 240 mg/L | Activated sludge process | TOC: 9900 mg/L | >90 % | |
| 170 mg/L | TOC: 20200 mg/L | >90 % | ||||
| 2580 mg/L | TOC: 29250 mg/L | >90 % | ||||
| Abacavir | Municipal wastewater | ~30 ng/L | Aerobic treatment system | HRT: 9.9–11.4 h | ~80 % | |
| Acyclovir | 600 ng/L | ~65 % | ||||
| Emtricitabine | 15–20 ng/L | <10 % | ||||
| Lamivudine | 90–100 ng/L | ~70–75 % | ||||
| Acyclovir | Hospital wastewater | – | Activated sludge treatment | Dissolved oxygen concentration: 8 mg/L | ~70 % | |
| Famciclovir | 100 % | |||||
| Penciclovir | ~90 % | |||||
| Valaciclovir | 100 % | |||||
| Acyclovir | Milli-Q water | 15 mg/L | Activated sludge treatment with the addition of nitrifying culture | HRT: 24 h | 65.1 % | |
| 15 μg/L | 88.2 % | |||||
| Acyclovir | Urban and hospital wastewater | – | Aerobic biological treatment | Secondary treatment with disinfection | ~80 % | |
| Acyclovir | Pharmaceutical wastewater | 154 mg/L | Membrane bioreactor | Feed flow rate: 1.6 L/day | ~98 % | |
| Acyclovir | Wastewater treatment effluent | – | Membrane bioreactor | MBR system volume: 250 L | 60–90 % | |
| Abacavir | Municipal wastewater | ~30 ng/L | Staged anaerobic fluidized membrane bioreactor | Flow rate: 5.5 m3/day | ~80 % | |
| Acyclovir | 600 ng/L | >95 % | ||||
| Emtricitabine | 15–20 ng/L | ~50 % | ||||
| Lamivudine | 90–100 ng/L | >90 % |